CoChat

ER stress-induced mediator C/EBP homologous protein thwarts effector T cell activity in tumors through T-bet repression

Open access

The DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.

Abstract

Understanding the intrinsic mediators that render CD8+ T cells dysfunctional in the tumor microenvironment is a requirement to develop more effective cancer immunotherapies. Here, we report that C/EBP homologous protein (Chop), a downstream sensor of severe endoplasmic reticulum (ER) stress, is a major negative regulator of the effector function of tumor-reactive CD8+ T cells. Chop expression is increased in tumor-infiltrating CD8+ T cells, which correlates with poor clinical outcome in ovarian cancer patients. Deletion of Chop in T cells improves spontaneous antitumor CD8+ T cell immunity and boosts the efficacy of T cell-based immunotherapy. Mechanistically, Chop in CD8+ T cells is elevated primarily through the ER stress-associated kinase Perk and a subsequent induction of Atf4; and directly represses the expression of T-bet, a master regulator of effector T cell function. These findings demonstrate the primary role of Chop in tumor-induced CD8+ T cell dysfunction and the therapeutic potential of blocking Chop or ER stress to unleash T cell-mediated antitumor immunity.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-019-09263-1

Cites

60 of 60 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Increased Chop in CD8+ tumor-infiltrating T lymphocytes (TILs) correlates with poor survival in ovarian cancer. a Ddit3 mRNA levels in tumor-associated CD45+ CD8+ T cells (TILs) sorted from subcutaneous 3LL, EL-4, MCA-38, or B16 tumors and CD8+ T cells from the spleens of the same tumor-bearing mice (Tumor bearing) or tumor-free mice (Tumor free). Bar graphs show the mean ± s.e.m. (n = 5 mice/group). b Chop expression in CD8+ TILs from B16 melanoma tumors (left) and 3LL tumors (right), compared with splenic CD8+ T cells from the corresponding tumor-bearing mice. Chop was detected by fluorescence-activated cell sorter and levels indicated by mean fluorescence intensity (MFI). Representative findings from four repeats. c CHOP in CD8+ TILs from ovarian carcinoma patients (Ovarian Ca tumor, n = 18) compared to peripheral blood CD8+ T cells from ovarian carcinoma patients (Ovarian Ca blood, n = 11) or healthy controls (Healthy blood, n = 6). d CHOP levels in autologous CD8+ TILs (Tumor) and peripheral blood CD8+ T cells (Blood) from ovarian carcinoma patients (n = 7). e Representative image (scale 10 μm) showing CHOP expression in CD8+ TILs from ovarian carcinoma patients compared to CD8+ T cells from healthy ovarian tissues. Isotype (red) or CHOP (red, tested by clone 9C8 (left) or polyclonal antibody R-20 (right)), CD8 (green) and DAPI (blue) were detected by confocal microscopy. f Percentage of nuclear CHOP+ cells (clone 9C8) among tumor-associated CD8+ T lymphocytes in a tissue microarray containing advanced ovarian carcinoma tissues (n = 87) vs. normal ovarian tissues (n = 12). g Overall survival in advanced ovarian tumor patients having increased frequency of nuclear CHOP in CD8+ TILs (CHOPhigh) (n = 52) vs. those having low frequency of nuclear CHOP in CD8+ TILs (CHOPlow) (n = 29) (logrank 4.39, p = 0.0361 using Gehan–Breslow–Wilcoxon test; cutoff was established as described in the Methods section). Studies were developed using the anti-CHOP antibody clone 9C8. h Percentage of CD8+ TILs having nuclear CHOP (clone 9C8) in ovarian cancer patients that had optimal (n = 59) vs. suboptimal (n = 23) cytoreductive debulking surgery. Bar graphs represent mean value ± s.e.m., *p < 0.05, **p < 0.01, ***p < 0.001 were calculated using two-tailed unpaired Student’s t test
Fig. 1 Increased Chop in CD8+ tumor-infiltrating T lymphocytes (TILs) correlates with poor survival in ovarian cancer. a Ddit3 mRNA levels in tumor-associated CD45+ CD8+ T cells (TILs) sorted from subcutaneous 3LL, EL-4, MCA-38, or B16 tumors and CD8+ T cells from the spleens of the same tumor-bearing mice (Tumor bearing) or tumor-free mice (Tumor free). Bar graphs show the mean ± s.e.m. (n = 5 mice/group). b Chop expression in CD8+ TILs from B16 melanoma tumors (left) and 3LL tumors (right), compared with splenic CD8+ T cells from the corresponding tumor-bearing mice. Chop was detected by fluorescence-activated cell sorter and levels indicated by mean fluorescence intensity (MFI). Representative findings from four repeats. c CHOP in CD8+ TILs from ovarian carcinoma patients (Ovarian Ca tumor, n = 18) compared to peripheral blood CD8+ T cells from ovarian carcinoma patients (Ovarian Ca blood, n = 11) or healthy controls (Healthy blood, n = 6). d CHOP levels in autologous CD8+ TILs (Tumor) and peripheral blood CD8+ T cells (Blood) from ovarian carcinoma patients (n = 7). e Representative image (scale 10 μm) showing CHOP expression in CD8+ TILs from ovarian carcinoma patients compared to CD8+ T cells from healthy ovarian tissues. Isotype (red) or CHOP (red, tested by clone 9C8 (left) or polyclonal antibody R-20 (right)), CD8 (green) and DAPI (blue) were detected by confocal microscopy. f Percentage of nuclear CHOP+ cells (clone 9C8) among tumor-associated CD8+ T lymphocytes in a tissue microarray containing advanced ovarian carcinoma tissues (n = 87) vs. normal ovarian tissues (n = 12). g Overall survival in advanced ovarian tumor patients having increased frequency of nuclear CHOP in CD8+ TILs (CHOPhigh) (n = 52) vs. those having low frequency of nuclear CHOP in CD8+ TILs (CHOPlow) (n = 29) (logrank 4.39, p = 0.0361 using Gehan–Breslow–Wilcoxon test; cutoff was established as described in the Methods section). Studies were developed using the anti-CHOP antibody clone 9C8. h Percentage of CD8+ TILs having nuclear CHOP (clone 9C8) in ovarian cancer patients that had optimal (n = 59) vs. suboptimal (n = 23) cytoreductive debulking surgery. Bar graphs represent mean value ± s.e.m., *p < 0.05, **p < 0.01, ***p < 0.001 were calculated using two-tailed unpaired Student’s t testCC BY · PubMed Central
Fig. 2 Perk regulates Chop expression in primed CD8+ T cells and CD8+ TILs. a Upper panel: Time-dependent induction of Chop in murine (left) and human (right) T cells primed in vitro. T cells were stimulated with anti-CD3/CD28 and collected at the indicated time points (0–72 h). Lower panel: Densitometry quantitation of immunoblots (n = 3). b Carboxyfluorescein succinimidyl ester-labeled Pmel CD8+ T cells (CD90.1+) were transferred into wild-type mice (CD90.2+), followed or not by vaccination with gp10025–33 plus IFA. On day 4, Chop levels by mean fluorescence intensity (MFI) (left) and percentage of Chop+ cells (right) were established by fluorescence-activated cell sorter (FACS) in gated CD8+ CD90.1+ T cells from lymph nodes of vaccinated vs. non-vaccinated mice (n = 3). c Left: Tauroursodeoxycholic acid (0.5 mM, at time 0) or Thapsigargin (100 nM, after 48 h) were added to CD8+ T cells stimulated with plate-bond anti-CD3/CD28. Protein extracts were collected 72 h post-activation. Right: Quantitation of immunoblots (n = 3). d Unfolded protein response mediators Perk, Ire-1α, and Atf4 in stimulated murine (left) and human (right) T cells (0–72 h). Representative Immunoblot from n = 3. e CD8+ T cells from Eif2ak3flox or Eif2ak3T cell-KO mice were primed with anti-CD3/CD28 for 0–72 h. Upper panel: Chop and Perk detected by immunoblotting; lower panel: Densitometry quantitation of immunoblots (n = 3). f Chop MFI levels in CD8+ TILs from B16-bearing Eif2ak3flox and Eif2ak3T cell-KO mice (n = 3). Chop was detected in viable CD45+CD8+ TILs by FACS (left) and MFI values compiled (right). g Representative reactive oxygen species levels in murine and human DHE-labeled CD8+ T cells activated with anti-CD3/CD28 and treated for 24 h with 5% cell-free ovarian ascites obtained from mice bearing ID8-Defb29/Vegf-a ovarian tumors or 5% primary ascites from patients with ovarian cancer, respectively (n = 4). h Murine CD8+ T cells were primed with anti-CD3/CD28 for 48 h and then cultured with or without ID8-Defb29/Vegf-a cell-free ovarian tumors ascites for 24 h (n = 3). i CD8+ T cells treated as in h were cultured in the presence or the absence of 2 mM L-NAC during the ascites treatment (n = 3). Bar graphs represent mean ± s.e.m., *p < 0.05 was calculated using two-tailed unpaired Student’s t test
Fig. 2 Perk regulates Chop expression in primed CD8+ T cells and CD8+ TILs. a Upper panel: Time-dependent induction of Chop in murine (left) and human (right) T cells primed in vitro. T cells were stimulated with anti-CD3/CD28 and collected at the indicated time points (0–72 h). Lower panel: Densitometry quantitation of immunoblots (n = 3). b Carboxyfluorescein succinimidyl ester-labeled Pmel CD8+ T cells (CD90.1+) were transferred into wild-type mice (CD90.2+), followed or not by vaccination with gp10025–33 plus IFA. On day 4, Chop levels by mean fluorescence intensity (MFI) (left) and percentage of Chop+ cells (right) were established by fluorescence-activated cell sorter (FACS) in gated CD8+ CD90.1+ T cells from lymph nodes of vaccinated vs. non-vaccinated mice (n = 3). c Left: Tauroursodeoxycholic acid (0.5 mM, at time 0) or Thapsigargin (100 nM, after 48 h) were added to CD8+ T cells stimulated with plate-bond anti-CD3/CD28. Protein extracts were collected 72 h post-activation. Right: Quantitation of immunoblots (n = 3). d Unfolded protein response mediators Perk, Ire-1α, and Atf4 in stimulated murine (left) and human (right) T cells (0–72 h). Representative Immunoblot from n = 3. e CD8+ T cells from Eif2ak3flox or Eif2ak3T cell-KO mice were primed with anti-CD3/CD28 for 0–72 h. Upper panel: Chop and Perk detected by immunoblotting; lower panel: Densitometry quantitation of immunoblots (n = 3). f Chop MFI levels in CD8+ TILs from B16-bearing Eif2ak3flox and Eif2ak3T cell-KO mice (n = 3). Chop was detected in viable CD45+CD8+ TILs by FACS (left) and MFI values compiled (right). g Representative reactive oxygen species levels in murine and human DHE-labeled CD8+ T cells activated with anti-CD3/CD28 and treated for 24 h with 5% cell-free ovarian ascites obtained from mice bearing ID8-Defb29/Vegf-a ovarian tumors or 5% primary ascites from patients with ovarian cancer, respectively (n = 4). h Murine CD8+ T cells were primed with anti-CD3/CD28 for 48 h and then cultured with or without ID8-Defb29/Vegf-a cell-free ovarian tumors ascites for 24 h (n = 3). i CD8+ T cells treated as in h were cultured in the presence or the absence of 2 mM L-NAC during the ascites treatment (n = 3). Bar graphs represent mean ± s.e.m., *p < 0.05 was calculated using two-tailed unpaired Student’s t testCC BY · PubMed Central
Fig. 3 Chop negatively regulates effector CD8+ T cell activity. a Gene set enrichment analysis was performed to determine the specific enrichment in effector CD8+ T cell gene signature in primed wild-type or Ddit3−/− Pmel CD8+ T cells. b Heatmap showing the expression of selective effector function-related transcripts in primed wild-type vs. Ddit3−/− Pmel CD8+ T cells, as described in the Methods section. c Carboxyfluorescein succinimidyl ester (CFSE)-labeled wild-type or Ddit3−/− CD8+ T cells were stimulated with anti-CD3/CD28 and proliferation tested after 72 h by fluorescence-activated cell sorter (FACS). Left: representative histogram of T cell proliferation (n = 6); right: T cell proliferation rates under different concentrations of anti-CD3/CD28 (µg/ml) (n = 6). d Granzyme B protein (upper panel, long- and short-time exposure) and Gzmb mRNA levels (lower panel) in wild-type or Ddit3−/− CD8+ T cells primed with anti-CD3/CD28 for 72 h (n = 5). e Percentage of IFNγ+ cells in wild-type or Ddit3−/− CD8+ T cells primed as in (d). Right: representative FACS findings; left: merged percentage values from n = 4. f Extracellular acidification rate (ECAR) of wild-type or Ddit3−/− CD8+ T cells primed as in d upon glycolysis stress analysis (n = 3). g Oxygen consumption rate (OCR) of wild-type or Ddit3−/− CD8+ T cells activated as in d after mitochondrial stress analysis (n = 3). h, i Percentage of IFNγ+ cells in CD8+ T cells primed in the presence of Tauroursodeoxycholic acid (n = 4) (h) or from Eif2ak3flox or Eif2ak3T cell-KO mice (n = 5) (i). j In vitro cytotoxicity of wild-type and Ddit3−/− CD8+ Tcells was assessed by measuring EL-4 cell proportion after co-culturing gp10025–33 pre-activated wild-type or Ddit3−/− Pmel CD8+ T cells with EL-4 cells loaded with gp10025–33 or control peptide (high or low CFSE, respectively). Cytotoxicity was evaluated after 24 h of co-culture by FACS. Right: representative FACS result; left: merged results from n = 5. k Representative result of CD44high CD62L− effector memory cells in wild-type or Ddit3-null CD8+ T cells primed as in d (n = 10). Bar graphs represent mean ± s.e.m., *p < 0.05, **p < 0.01 were calculated using two-tailed unpaired Student’s t test
Fig. 3 Chop negatively regulates effector CD8+ T cell activity. a Gene set enrichment analysis was performed to determine the specific enrichment in effector CD8+ T cell gene signature in primed wild-type or Ddit3−/− Pmel CD8+ T cells. b Heatmap showing the expression of selective effector function-related transcripts in primed wild-type vs. Ddit3−/− Pmel CD8+ T cells, as described in the Methods section. c Carboxyfluorescein succinimidyl ester (CFSE)-labeled wild-type or Ddit3−/− CD8+ T cells were stimulated with anti-CD3/CD28 and proliferation tested after 72 h by fluorescence-activated cell sorter (FACS). Left: representative histogram of T cell proliferation (n = 6); right: T cell proliferation rates under different concentrations of anti-CD3/CD28 (µg/ml) (n = 6). d Granzyme B protein (upper panel, long- and short-time exposure) and Gzmb mRNA levels (lower panel) in wild-type or Ddit3−/− CD8+ T cells primed with anti-CD3/CD28 for 72 h (n = 5). e Percentage of IFNγ+ cells in wild-type or Ddit3−/− CD8+ T cells primed as in (d). Right: representative FACS findings; left: merged percentage values from n = 4. f Extracellular acidification rate (ECAR) of wild-type or Ddit3−/− CD8+ T cells primed as in d upon glycolysis stress analysis (n = 3). g Oxygen consumption rate (OCR) of wild-type or Ddit3−/− CD8+ T cells activated as in d after mitochondrial stress analysis (n = 3). h, i Percentage of IFNγ+ cells in CD8+ T cells primed in the presence of Tauroursodeoxycholic acid (n = 4) (h) or from Eif2ak3flox or Eif2ak3T cell-KO mice (n = 5) (i). j In vitro cytotoxicity of wild-type and Ddit3−/− CD8+ Tcells was assessed by measuring EL-4 cell proportion after co-culturing gp10025–33 pre-activated wild-type or Ddit3−/− Pmel CD8+ T cells with EL-4 cells loaded with gp10025–33 or control peptide (high or low CFSE, respectively). Cytotoxicity was evaluated after 24 h of co-culture by FACS. Right: representative FACS result; left: merged results from n = 5. k Representative result of CD44high CD62L− effector memory cells in wild-type or Ddit3-null CD8+ T cells primed as in d (n = 10). Bar graphs represent mean ± s.e.m., *p < 0.05, **p < 0.01 were calculated using two-tailed unpaired Student’s t testCC BY · PubMed Central
Fig. 4 Chop negatively regulates T-bet expression. a Time-dependent expression (upper panel) and corresponding densitometry quantitation (lower panel) of T-bet in primed wild-type and Ddit3−/− CD8+ T cells. Left: protein level (0–72 h); right: Tbx21 mRNA levels 48 h post-activation. CD8+ T cells were stimulated with plate-bound anti-CD3/CD28 (n = 3). b Tbx21 and Ifng mRNA expression in activated CD8+ T cells infected with control retrovirus (Retro-Ctrl) or Ddit3-expressing retrovirus (Retro-Chop). Cells were primed for 48 h and then infected for additional 48 h in the presence of the stimulating anti-CD3/CD28 antibodies (n = 4). c Ifng, Il12b2, Cbfa3, and Cxcr3 mRNA levels in control vs. Ddit3−/− CD8+ T cells primed as in a (n = 5). d Predicted Chop-binding site in the Tbx21 promoter region (GGGTGCAATCTTC). e Chromatin immunoprecipitation assay for the endogenous binding of Chop to Tbx21 promoter in primed wild-type or Ddit3−/− CD8+ T cells. Chop-binding activity was measured by real-time quantitative PCR, compared with IgG binding activity after normalizing to the activity of anti-H3 (n = 4). f A dual luciferase system composed of 2x-CRE containing Firefly luciferase reporter and the control Renilla luciferase reporter was transfected into 293T cells in combination with Ddit3-expressing or control vectors. n = 4 experimental repeats. g Expression of Chop (left) and T-bet (right) by fluorescence-activated cell sorter (FACS) upon transduction of primed CD8+ T cells with green fluorescent protein (GFP)-coding retroviruses containing control or 8x-CRE sequences. Cells were primed for 48 h and then infected for another 48 h in the presence of the stimulating anti-CD3/CD28 antibodies plus interleukin (IL)-2 (50 U/ml). n = 3 independent repeats. h Interferon-γ (IFNγ) levels in primed CD8+ T cells transduced with: (1) GFP/CD90.1-expressing control virus (Ctrl); (2) Chop/CD90.1-expressing virus and GFP-expressing control virus (Chop); (3) CD90.1-expressing control virus and T-bet/GFP-expressing virus (T-bet); or (4) Chop/CD90.1-expressing virus and T-bet/GFP-expressing virus (Chop/T-bet). Cells were primed for 24 h and then transduced for additional 72 h in the presence of stimulating antibodies plus IL-2 (50 U/ml). Then IFNγ levels were detected by FACS in gated CD90.1+GFP+ cells. Right: Representative FACS result; left: Merged results from three independent experiments. In the bar graphs showing mean ± s.e.m., *p < 0.05, **p < 0.01 were calculated using two-tailed unpaired Student’s t test
Fig. 4 Chop negatively regulates T-bet expression. a Time-dependent expression (upper panel) and corresponding densitometry quantitation (lower panel) of T-bet in primed wild-type and Ddit3−/− CD8+ T cells. Left: protein level (0–72 h); right: Tbx21 mRNA levels 48 h post-activation. CD8+ T cells were stimulated with plate-bound anti-CD3/CD28 (n = 3). b Tbx21 and Ifng mRNA expression in activated CD8+ T cells infected with control retrovirus (Retro-Ctrl) or Ddit3-expressing retrovirus (Retro-Chop). Cells were primed for 48 h and then infected for additional 48 h in the presence of the stimulating anti-CD3/CD28 antibodies (n = 4). c Ifng, Il12b2, Cbfa3, and Cxcr3 mRNA levels in control vs. Ddit3−/− CD8+ T cells primed as in a (n = 5). d Predicted Chop-binding site in the Tbx21 promoter region (GGGTGCAATCTTC). e Chromatin immunoprecipitation assay for the endogenous binding of Chop to Tbx21 promoter in primed wild-type or Ddit3−/− CD8+ T cells. Chop-binding activity was measured by real-time quantitative PCR, compared with IgG binding activity after normalizing to the activity of anti-H3 (n = 4). f A dual luciferase system composed of 2x-CRE containing Firefly luciferase reporter and the control Renilla luciferase reporter was transfected into 293T cells in combination with Ddit3-expressing or control vectors. n = 4 experimental repeats. g Expression of Chop (left) and T-bet (right) by fluorescence-activated cell sorter (FACS) upon transduction of primed CD8+ T cells with green fluorescent protein (GFP)-coding retroviruses containing control or 8x-CRE sequences. Cells were primed for 48 h and then infected for another 48 h in the presence of the stimulating anti-CD3/CD28 antibodies plus interleukin (IL)-2 (50 U/ml). n = 3 independent repeats. h Interferon-γ (IFNγ) levels in primed CD8+ T cells transduced with: (1) GFP/CD90.1-expressing control virus (Ctrl); (2) Chop/CD90.1-expressing virus and GFP-expressing control virus (Chop); (3) CD90.1-expressing control virus and T-bet/GFP-expressing virus (T-bet); or (4) Chop/CD90.1-expressing virus and T-bet/GFP-expressing virus (Chop/T-bet). Cells were primed for 24 h and then transduced for additional 72 h in the presence of stimulating antibodies plus IL-2 (50 U/ml). Then IFNγ levels were detected by FACS in gated CD90.1+GFP+ cells. Right: Representative FACS result; left: Merged results from three independent experiments. In the bar graphs showing mean ± s.e.m., *p < 0.05, **p < 0.01 were calculated using two-tailed unpaired Student’s t testCC BY · PubMed Central
Fig. 5 Ddit3 null T cells exert promoted protective antitumor immunity. a Tumor growth in Ddit3flox (blue) or Ddit3T cell-KO (red) mice bearing B16 tumors. Average kinetics ± s.e.m (n = 15 mice/group). b Left: Representative result of IFNγ+ (upper panel) and TNF-α+ (lower panel), and right: IFNγ+ TNF-α+ in gated CD45+ CD8+ TILs from Ddit3flox or Ddit3T cell-KO mice bearing B16 tumors. Tumors were collected 18 days after B16 tumor injection. (n = 10 tumors/group). c Percentage of IFNγ+ (left), TNF-α+ (middle) and IFNγ+ TNF-α+ (right) CD8+ tumor-infiltrating T lymphocytes (TILs) in B16 tumors isolated from Ddit3flox or Ddit3T cell-KO mice. (n = 10 mice/group). d Frequency of CD44+ CD69+ effector CD8+ TILs in B16 tumors isolated from Ddit3flox or Ddit3T cell-KO mice. (n = 8 tumors/group). e Percentage of KLGR1high CD127low late effector CD8+ TILs in B16 tumors isolated from Ddit3flox or Ddit3T cell-KO mice. (n = 8 tumor/group). f B16 tumor growth in Ddit3flox (blue) or Ddit3T cell-KO (red) mice, with or without 400 µg α-CD8 antibody injection on every third day (green or orange, respectively). Average tumor volume kinetics ± s.e.m in 6 mice/group. g Tumor growth in Eif2ak3flox (blue) or Eif2ak3T cell-KO (red) mice bearing B16 tumors. Average kinetics of tumor volume ± s.e.m in 8 mice/group. In the bar graphs showing mean ± s.e.m., *p < 0.05, **p < 0.01, ***p < 0.001 were calculated using two-tailed unpaired Student’s t test
Fig. 5 Ddit3 null T cells exert promoted protective antitumor immunity. a Tumor growth in Ddit3flox (blue) or Ddit3T cell-KO (red) mice bearing B16 tumors. Average kinetics ± s.e.m (n = 15 mice/group). b Left: Representative result of IFNγ+ (upper panel) and TNF-α+ (lower panel), and right: IFNγ+ TNF-α+ in gated CD45+ CD8+ TILs from Ddit3flox or Ddit3T cell-KO mice bearing B16 tumors. Tumors were collected 18 days after B16 tumor injection. (n = 10 tumors/group). c Percentage of IFNγ+ (left), TNF-α+ (middle) and IFNγ+ TNF-α+ (right) CD8+ tumor-infiltrating T lymphocytes (TILs) in B16 tumors isolated from Ddit3flox or Ddit3T cell-KO mice. (n = 10 mice/group). d Frequency of CD44+ CD69+ effector CD8+ TILs in B16 tumors isolated from Ddit3flox or Ddit3T cell-KO mice. (n = 8 tumors/group). e Percentage of KLGR1high CD127low late effector CD8+ TILs in B16 tumors isolated from Ddit3flox or Ddit3T cell-KO mice. (n = 8 tumor/group). f B16 tumor growth in Ddit3flox (blue) or Ddit3T cell-KO (red) mice, with or without 400 µg α-CD8 antibody injection on every third day (green or orange, respectively). Average tumor volume kinetics ± s.e.m in 6 mice/group. g Tumor growth in Eif2ak3flox (blue) or Eif2ak3T cell-KO (red) mice bearing B16 tumors. Average kinetics of tumor volume ± s.e.m in 8 mice/group. In the bar graphs showing mean ± s.e.m., *p < 0.05, **p < 0.01, ***p < 0.001 were calculated using two-tailed unpaired Student’s t testCC BY · PubMed Central
Fig. 6 Ddit3 deletion or silencing increases the effect of T cell-based immunotherapy. a Working model of Pmel T cell adoptive transfer. CD90.2+ wild-type mice were injected subcutaneous with B16 tumors, and after 8 days, they received a single dose of cyclophosphamide (CTX). The next day, mice received 1 × 106 primed wild-type or Ddit3−/− or anti-sense oligonucleotide (ASO)-treated CD90.1+CD8+ Pmel T cells. b Tumor growth in B16-bearing mice (black) transferred with wild-type (blue) or Ddit3−/− (red) CD90.1+ CD8+ Pmel T cells. Average kinetics of tumor volume ± s.e.m. in 9 mice/group. c Percentage of IFNγ+ cells in CD90.1+ CD8+ tumor-infiltrating T lymphocytes (TILs) from B16 tumors 5 days after wild-type or Ddit3−/− CD8+ Pmel T cell transfer. (n = 7 tumors/group). d ELISpot for interferon-γ (IFNγ) in the spleens of B16 tumor-bearing mice 5 days after wild-type or Ddit3−/− Pmel T cell transfer exposed to gp10025–33 for 24 h. (n = 6 spleens/group). e T-bet in CD90.1+CD8+ TILs from B16 tumors 5 days after wild-type or Ddit3−/− CD8+ Pmel T cell transfer. Right: representative result; left: merged results from n = 4/group. f Tumor growth in B16-bearing CD90.2+ mice (black) that received wild-type CD90.1+CD8+ Pmel T cells that were non-treated (gray) or pretreated with ASO-Control (blue) or ASO-Ddit3 (red). Average tumor volume kinetics ± s.e.m. of 8 mice/group. g Percentage of IFNγ+ in CD90.1+ CD8+ TILs from B16 tumor-bearing mice transferred with control, ASO-Control, or ASO-Ddit3-pretreated CD90.1+ Pmel T cells. (n = 6 tumors/group). h IFNγ ELISpot in spleens collected from B16 tumor-bearing mice treated with Pmel T cells or ASO-Control or ASO-Ddit3-pretreated Pmel T cells. Spleens were collected 5 days after T cell transfer and exposed 24 h to gp10025–33. (n = 4). Bar graphs show mean value ± s.e.m. and *p < 0.05, ***p < 0.001 were calculated using two-tailed unpaired Student’s t test
Fig. 6 Ddit3 deletion or silencing increases the effect of T cell-based immunotherapy. a Working model of Pmel T cell adoptive transfer. CD90.2+ wild-type mice were injected subcutaneous with B16 tumors, and after 8 days, they received a single dose of cyclophosphamide (CTX). The next day, mice received 1 × 106 primed wild-type or Ddit3−/− or anti-sense oligonucleotide (ASO)-treated CD90.1+CD8+ Pmel T cells. b Tumor growth in B16-bearing mice (black) transferred with wild-type (blue) or Ddit3−/− (red) CD90.1+ CD8+ Pmel T cells. Average kinetics of tumor volume ± s.e.m. in 9 mice/group. c Percentage of IFNγ+ cells in CD90.1+ CD8+ tumor-infiltrating T lymphocytes (TILs) from B16 tumors 5 days after wild-type or Ddit3−/− CD8+ Pmel T cell transfer. (n = 7 tumors/group). d ELISpot for interferon-γ (IFNγ) in the spleens of B16 tumor-bearing mice 5 days after wild-type or Ddit3−/− Pmel T cell transfer exposed to gp10025–33 for 24 h. (n = 6 spleens/group). e T-bet in CD90.1+CD8+ TILs from B16 tumors 5 days after wild-type or Ddit3−/− CD8+ Pmel T cell transfer. Right: representative result; left: merged results from n = 4/group. f Tumor growth in B16-bearing CD90.2+ mice (black) that received wild-type CD90.1+CD8+ Pmel T cells that were non-treated (gray) or pretreated with ASO-Control (blue) or ASO-Ddit3 (red). Average tumor volume kinetics ± s.e.m. of 8 mice/group. g Percentage of IFNγ+ in CD90.1+ CD8+ TILs from B16 tumor-bearing mice transferred with control, ASO-Control, or ASO-Ddit3-pretreated CD90.1+ Pmel T cells. (n = 6 tumors/group). h IFNγ ELISpot in spleens collected from B16 tumor-bearing mice treated with Pmel T cells or ASO-Control or ASO-Ddit3-pretreated Pmel T cells. Spleens were collected 5 days after T cell transfer and exposed 24 h to gp10025–33. (n = 4). Bar graphs show mean value ± s.e.m. and *p < 0.05, ***p < 0.001 were calculated using two-tailed unpaired Student’s t testCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 60 references

Cited by

See all 161

Metadata

Authors
Cao, Y., Trillo-Tinoco, J., Sierra, R. A., Anadon, C., Dai, W., Mohamed, E., Cen, L., Costich, T. L., Magliocco, A., Marchion, D., Klar, R., Michel, S., Jaschinski, F., Reich, R. R., Mehrotra, S., Cubillos-Ruiz, J. R., Munn, D. H., Conejo-Garcia, J. R., & Rodriguez, P. C.
Affiliations
  • Moffitt Cancer Center (US)
  • Medical University of South Carolina (US)
  • Augusta University (US)
Venue
Nature Communications
Published
2019-03-20
Volume
10
Issue
1
Pages
1280-1280
ISSN
2041-1723 (ISSN-L)
OpenAlex
W2924317925
Cited by
161
References
60
Citations by year
2026: 25 · 2025: 27 · 2024: 24 · 2023: 20 · 2022: 27 · 2021: 22 · 2020: 12 · 2019: 4
FWCI
8.61
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Communications (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • U.S. Department of Defense (W81XWH1610438, W81XWH, P30-CA076292)
  • Moffitt Cancer Center (P30CA076292, Cancer Center Support Grant (CCSG) CA076292, CA076292)
  • National Institutes of Health (W81XWH)
  • National Cancer Institute (R01CA157664, U01CA232758, R01CA211229, CA076292, R01CA178687, R01CA184185, R01CA103320, R01CA124515, P30CA076292, P30CA010815)
  • Ovarian Cancer Academy
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Endoplasmic Reticulum Stress and Disease
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Keywords
C/EBP homologous protein, CHOP, endoplasmic reticulum stress, PERK, ATF4, T-bet, CD8+ T cell dysfunction, tumor microenvironment, ovarian cancer, antitumor immunity, T cell-based immunotherapy, tumor-infiltrating T cells
MeSH terms
Carcinoma, Ovarian Epithelial, T-bet Transcription Factor, Animals, Female, Humans, Immunity, Cellular, Ovarian Neoplasms, Gene Expression Regulation, Neoplastic, Survival Analysis, Lymphocytes, Tumor-Infiltrating, Mice, Knockout, CD8-Positive T-Lymphocytes, Adoptive Transfer, eIF-2 Kinase, T-Box Domain Proteins, Xenograft Model Antitumor Assays, RNA, Small Interfering, Cell Line, Tumor, Mice, Activating Transcription Factor 4, Transcription Factor CHOP, Tumor Microenvironment, Endoplasmic Reticulum Stress

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: ER stress-induced mediator C/EBP homologous protein thwarts effector T cell activity in tumors through T-bet repression. https://app.cochat.ai/papers/10.1038/s41467-019-09263-1
The paper
Cao, Y., Trillo-Tinoco, J., Sierra, R. A., Anadon, C., Dai, W., Mohamed, E., Cen, L., Costich, T. L., Magliocco, A., Marchion, D., Klar, R., Michel, S., Jaschinski, F., Reich, R. R., Mehrotra, S., Cubillos-Ruiz, J. R., Munn, D. H., Conejo-Garcia, J. R., & Rodriguez, P. C. (2019). ER stress-induced mediator C/EBP homologous protein thwarts effector T cell activity in tumors through T-bet repression. Nature Communications. https://doi.org/10.1038/s41467-019-09263-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.